Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Vanda (VNDA) yesterday and set a price target of $12.00. The company’s shares closed last Monday at $11.32, close to its 52-week low of $10.10.
According to TipRanks.com, Rajavelu is a 1-star analyst with an average return of -4.8% and a 39.7% success rate. Rajavelu covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Teva Pharmaceutical Industries, and Arrowhead Pharmaceuticals.
Currently, the analyst consensus on Vanda is a Hold with an average price target of $15.50, implying a 53.5% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Hold rating on the stock with a $13.00 price target.
See today’s analyst top recommended stocks >>
Vanda’s market cap is currently $603.8M and has a P/E ratio of 5.35. The company has a Price to Book ratio of 1.51.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VNDA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. It intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051.